期刊文献+

依布利特与普罗帕酮转复心房颤动和心房扑动的临床研究 被引量:3

下载PDF
导出
摘要 目的评价静脉注射依布利特和普罗帕酮转复心房颤动和心房扑动的有效性和安全性。方法本研究采用随机单盲、平行对照研究。共入选发作持续时间1 h^4 d的房颤、房扑患者30例,其中房颤27例,房扑3例,随机进入依布利特组(n=16)、普罗帕酮组(n=14)。两组分别在心电、血压监测下于10 min内静脉注射依布利特1 mg或普罗帕酮70 mg,如给药后10min仍未转复为窦性心律,各组重复前述治疗1次,观察开始给药后1.5 h内房颤、房扑的转复率及4 h内的不良反应。结果①依布利特转复房颤、房扑的成功率高于普罗帕酮(57.1%vs 43.7%),但差异无统计学意义(P>0.05);②依布利特转复房颤、房扑所用时间的明显短于普罗帕酮,给药后30 min中内依布利特的转复率达100%,普罗帕酮的转复率为85.7%,但差异无统计学意义(P>0.05);③依布利特治疗组的不良反应表现为短阵室速、连发室早,均未经特殊处理很快消失。有1例出现Ⅰ度房室传导阻滞,未经特殊处理。结论依布利特能有效、快速、安全的转复近期发作的心房颤动和心房扑动。
出处 《中国急救医学》 CAS CSCD 北大核心 2006年第6期467-468,共2页 Chinese Journal of Critical Care Medicine
  • 相关文献

参考文献11

  • 1Waldo AL, Pratt CM. Introduction: acute treatment of atrial fibrillation and flutter- ibutilide in perspective[J]. Am J Cardiol, 1996,78(8A): 1 -2.
  • 2Pritchett, EL. Management of atrial fibrillation[J]. N Engl J Med, 1992,326(19) : 1264 - 1271.
  • 3Prystowsky EN, Benson DW, Fuster V, et al. Management of patients with atrial fibrillation. A statement for healthcare professiontds. From the subcommittee on Electrocardiography and Electrophysiology, American Heart Association[J]. Circulation, 1996,93 (6) :1262- 1277.
  • 4Miller MR , McNamara RL , Segal JB , et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta- analysis of clinical trials[J]. J Fam Pract,2000, 49(11): 1033- 1046.
  • 5Varriale P , Sedighi A. Acute management of atrial fibrillation and atrial flutter in the critical care unit : Mould it be ibutilide[J]? Clin Cardiol ,2000 , 23(4) : 265- 268.
  • 6Volgman AS, Carberry PA, Stambler B , et al . Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation[J]. J Am Coll Cardiol , 1998 ,31(6) : 1414- 1419.
  • 7张海澄,郭继鸿,方全,郑亚安,孙跃民,朱文青,万征,郭静萱,葛均波,韩少梅.静脉注射伊布利特与普罗帕酮转复心房颤动和扑动的多中心研究[J].中华医学杂志,2005,85(12):798-801. 被引量:43
  • 8Vanderlugt JT, Mattioni T, Denker S, et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery [J]. Circulation, 1999, 100(4) :369 - 375.
  • 9Kowey PR , Vanderlugt JT, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/ flutter [ J ]. Am J Cardiol, 1996, 78(8A) : 46 - 52.
  • 10Rogers KC , Wolfe DA . Ibutilide : a class Ⅲ rapidly acting antidysrhythmic for atrial fibrillatin of atrial flutter [ J ] . J Emergency Med, 2001,20(1) :67 - 71.

二级参考文献8

  • 1Miller MR, McNamara RL, Segal JB,et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a Meta analysis of clinical trials. J Fam Pract,2000,49:1033-1046.
  • 2Cropp Js, Antal EG, Talbert RL,et al. Ibutilide: a new class Ⅲ antiarrhythmic agent. Parmarcotherapy, 1997,17:1-9.
  • 3Lych JR, Baskin EP, Nutt EM, et al, Comparision of binding to rapidly activating delayed rectifier K channel, Ikr and effects on myocardial refractoriness for class Ⅲ antiarrythmic agents. J Cardiovasc Pharmacol, 1995,25:336-340.
  • 4Naccarelli GV, Lee KS, Gibson JK, et al. Electrophysiology and pharmacology of Ibutilide. Am J Cardiol,1996,78(8A): 12-16.
  • 5Baskin EP , Lynch JJ Jr. Differential atrial versus ventricular activities of class Ⅲ potassium channel blockers. Pharmacol Exp Ther, 1998,285:135-142.
  • 6Ellenbogen KA, Stambler BS, Wood MA, et al . Efficacy of intravenous Ibutilide for rapid termination of atrial fibrillation and atril flutter: a dose-response study. J Am Coll Cardiol, 1996, 28: 130-136.
  • 7Gowdw RM, Punukollu G, Khan LA, et al. Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety. Am J Ther, 2003,10: 259-263.
  • 8Kowey PR, Vanderlugt JT, Luderer JR. Safety and risk/benefit analysis of Ibutilide for acute conversion of atrial fibrillation/flutter. Am J Cardiol , 1996,78 (suppl 8A): 46-52.

共引文献42

同被引文献15

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部